Neurocytome central

Moussa, Ronald; Abadjian, Gerard; Nader, Mark Abi; Rizk, T.; Samaha, Elie; Nohra, G.; Checrallah, Antoine; Okais, N

doi:10.1016/s0028-3770(04)98455-x

Cited by 10 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients may also experience nausea, vomiting, headache, seizures, decreased consciousness, weakness, and memory or vision problems [47303854555657]. In rare cases, intraventricular hemorrhage may also occur [58].…”

Section: Clinical Manifestationsmentioning

confidence: 99%

Central Neurocytoma: A Review of Clinical Management and Histopathologic Features

Lee

Bui

Chen

et al. 2016

Brain Tumor Res Treat

View full text Add to dashboard Cite

Central neurocytoma (CN) is a rare, benign brain tumor often located in the lateral ventricles. CN may cause obstructive hydrocephalus and manifest as signs of increased intracranial pressure. The goal of treatment for CN is a gross total resection (GTR), which often yields excellent prognosis with a very high rate of tumor control and survival. Adjuvant radiosurgery and radiotherapy may be considered to improve tumor control when GTR cannot be achieved. Chemotherapy is also not considered a primary treatment, but has been used as a salvage therapy. The radiological features of CN are indistinguishable from those of other brain tumors; therefore, many histological markers, such as synaptophysin, can be very useful for diagnosing CNs. Furthermore, the MIB-1 Labeling Index seems to be correlated with the prognosis of CN. We also discuss oncogenes associated with these elusive tumors. Further studies may improve our ability to accurately diagnose CNs and to design the optimal treatment regimens for patients with CNs.

show abstract

Section: Clinical Manifestationsmentioning

confidence: 99%

Central Neurocytoma: A Review of Clinical Management and Histopathologic Features

Lee

Bui

Chen

et al. 2016

Brain Tumor Res Treat

View full text Add to dashboard Cite

show abstract

“…By definition, CN is located in the ventricular system. As such, patients often present with headaches, nausea, or vomiting consistent with an obstructive pattern of hydrocephalus [347891011121314151617]. Computed tomography images demonstrate a heterogeneously hyperdense, enhancing mass.…”

Section: Introductionmentioning

confidence: 99%

Systematic Analysis of Clinical Outcomes Following Stereotactic Radiosurgery for Central Neurocytoma

Bui

Lagman

Chung

et al. 2017

Brain Tumor Res Treat

View full text Add to dashboard Cite

Central neurocytoma (CN) typically presents as an intraventricular mass causing obstructive hydrocephalus. The first line of treatment is surgical resection with adjuvant conventional radiotherapy. Stereotactic radiosurgery (SRS) was proposed as an alternative therapy for CN because of its lower risk profile. The objective of this systematic analysis is to assess the efficacy of SRS for CN. A systematic analysis for CN treated with SRS was conducted in PubMed. Baseline patient characteristics and outcomes data were extracted. Heterogeneity and publication bias were also assessed. Univariate and multivariate linear regressions were used to test for correlations to the primary outcome: local control (LC). The estimated cumulative rate of LC was 92.2% (95% confidence interval: 86.5-95.7%, p<0.001). Mean follow-up time was 62.4 months (range 3-149 months). Heterogeneity and publication bias were insignificant. The univariate linear regression models for both mean tumor volume and mean dose were significantly correlated with improved LC (p<0.001). Our data suggests that SRS may be an effective and safe therapy for CN. However, the rarity of CN still limits the efficacy of a quantitative analysis. Future multi-institutional, randomized trials of CN patients should be considered to further elucidate this therapy.

show abstract